We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Read MoreHide Full Article
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company to watch right now is Merck KGaA (MKKGY - Free Report) . MKKGY is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value.
Investors will also notice that MKKGY has a PEG ratio of 1.85. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. MKKGY's PEG compares to its industry's average PEG of 1.99. Over the past 52 weeks, MKKGY's PEG has been as high as 2.31 and as low as 1.40, with a median of 2.01.
Finally, investors will want to recognize that MKKGY has a P/CF ratio of 6.30. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 12.68. MKKGY's P/CF has been as high as 17.18 and as low as 5.95, with a median of 7.25, all within the past year.
USANA Health Sciences (USNA - Free Report) may be another strong Medical - Drugs stock to add to your shortlist. USNA is a Zacks Rank of #2 (Buy) stock with a Value grade of A.
USANA Health Sciences is trading at a forward earnings multiple of 10.36 at the moment, with a PEG ratio of 0.86. This compares to its industry's average P/E of 42.68 and average PEG ratio of 1.99.
Over the last 12 months, USNA's P/E has been as high as 17.00, as low as 7.83, with a median of 11.26, and its PEG ratio has been as high as 1.42, as low as 0.65, with a median of 0.94.
Additionally, USANA Health Sciences has a P/B ratio of 1.11 while its industry's price-to-book ratio sits at 1.63. For USNA, this valuation metric has been as high as 1.72, as low as 0.83, with a median of 1.22 over the past year.
These are only a few of the key metrics included in Merck KGaA and USANA Health Sciences strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, MKKGY and USNA look like an impressive value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company to watch right now is Merck KGaA (MKKGY - Free Report) . MKKGY is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value.
Investors will also notice that MKKGY has a PEG ratio of 1.85. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. MKKGY's PEG compares to its industry's average PEG of 1.99. Over the past 52 weeks, MKKGY's PEG has been as high as 2.31 and as low as 1.40, with a median of 2.01.
Finally, investors will want to recognize that MKKGY has a P/CF ratio of 6.30. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 12.68. MKKGY's P/CF has been as high as 17.18 and as low as 5.95, with a median of 7.25, all within the past year.
USANA Health Sciences (USNA - Free Report) may be another strong Medical - Drugs stock to add to your shortlist. USNA is a Zacks Rank of #2 (Buy) stock with a Value grade of A.
USANA Health Sciences is trading at a forward earnings multiple of 10.36 at the moment, with a PEG ratio of 0.86. This compares to its industry's average P/E of 42.68 and average PEG ratio of 1.99.
Over the last 12 months, USNA's P/E has been as high as 17.00, as low as 7.83, with a median of 11.26, and its PEG ratio has been as high as 1.42, as low as 0.65, with a median of 0.94.
Additionally, USANA Health Sciences has a P/B ratio of 1.11 while its industry's price-to-book ratio sits at 1.63. For USNA, this valuation metric has been as high as 1.72, as low as 0.83, with a median of 1.22 over the past year.
These are only a few of the key metrics included in Merck KGaA and USANA Health Sciences strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, MKKGY and USNA look like an impressive value stock at the moment.